• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Kezar Life Sciences, Inc. - Common Stock (NQ:KZR)

    6.250 -0.020 (-0.32%)
    Streaming Delayed Price Updated: 4:00 PM EST, Jan 6, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 3,177
    Open 6.270
    Bid (Size) 6.010 (300)
    Ask (Size) 6.290 (100)
    Prev. Close 6.270
    Today's Range 6.235 - 6.270
    52wk Range 3.533 - 6.930
    Shares Outstanding 72,407,215
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Kezar Life Sciences Reports Third Quarter 2025 Financial Results
    From Kezar Life Sciences, Inc.
    Via Business Wire
    News headline image
    Kezar Life Sciences Announces Presentation of PORTOLA Data at the American Association for the Study of Liver Disease (AASLD) – The Liver Meeting® 2025
    From Kezar Life Sciences, Inc.
    Via Business Wire

    Performance

    YTD
    -0.6%
    -0.6%
    1 Month
    -0.5%
    -0.5%
    3 Month
    +61.9%
    +61.9%
    6 Month
    +38.0%
    +38.0%
    1 Year
    -6.0%
    -6.0%

    More News

    Read More
    News headline image
    Kezar Launches Strategic Review As FDA Roadblock Derails Liver Drug Plans ↗
    Via Benzinga
    News headline image
    Looking Into Kezar Life Sciences's Recent Short Interest ↗
    Via Benzinga
    News headline image
    Kezar Life Sciences Stock Hit With Downgrades And Price Target Cuts: Retail Keeps Hopes Alive ↗
    Via Stocktwits
    Topics Workforce
    News headline image
    12 Health Care Stocks Moving In Friday's Intraday Session ↗
    Via Benzinga
    News headline image
    This Booz Allen Hamilton Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday ↗
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    Why CSX Shares Are Trading Higher By Over 4%; Here Are 20 Stocks Moving Premarket ↗
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Thursday's After-Market Session ↗
    Via Benzinga
    News headline image
    Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis and Plans to Explore Strategic Alternatives
    From Kezar Life Sciences, Inc.
    Via Business Wire
    News headline image
    Kezar Life Sciences to Participate in Two Upcoming Investor Conferences
    From Kezar Life Sciences
    Via Business Wire
    News headline image
    Kezar Narrows Loss 37 Percent in Q2 ↗
    Via The Motley Fool
    News headline image
    Kezar Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update
    From Kezar Life Sciences, Inc.
    Via Business Wire
    News headline image
    FDA Lifts Pause On Kezar's Liver Drug Trial—Next Stop Lupus Study ↗
    Via Benzinga
    News headline image
    Kezar Life Sciences Announces FDA Has Lifted Partial Clinical Hold on PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis
    From Kezar Life Sciences, Inc.
    Via Business Wire
    News headline image
    Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference
    From Kezar Life Sciences, Inc.
    Via Business Wire
    News headline image
    Kezar Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update
    From Kezar Life Sciences, Inc.
    Via Business Wire
    News headline image
    Kezar Life Sciences Touts Positive Data From Mid-Stage Study For Chronic Liver Disease Drug Candidate ↗
    Via Benzinga
    News headline image
    Kezar Life Sciences Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (AIH) and Reports Fourth Quarter and Year End 2024 Financial Results
    From Kezar Life Sciences, Inc.
    Via Business Wire
    News headline image
    Kezar Life Sciences to Present Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis on March 25, 2025
    From Kezar Life Sciences, Inc.
    Via Business Wire
    News headline image
    Kezar Life Sciences to Present at Virtual KOL Event Hosted by William Blair on Zetomipzomib Clinical Development in Autoimmune Hepatitis and Provide a Safety Update from the PALIZADE Trial for Lupus Nephritis on February 27, 2025
    From Kezar Life Sciences, Inc.
    Via Business Wire
    News headline image
    Kezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update
    From Kezar Life Sciences, Inc.
    Via Business Wire
    News headline image
    Glancy Prongay & Murray LLP Announces Investigation of Kezar Life Sciences, Inc. (KZR)
    From Glancy Prongay & Murray LLP
    Via Business Wire
    News headline image
    Kezar Life Sciences Announces 1-for-10 Reverse Stock Split
    From Kezar Life Sciences
    Via Business Wire

    Frequently Asked Questions

    Is Kezar Life Sciences, Inc. - Common Stock publicly traded?
    Yes, Kezar Life Sciences, Inc. - Common Stock is publicly traded.
    What exchange does Kezar Life Sciences, Inc. - Common Stock trade on?
    Kezar Life Sciences, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Kezar Life Sciences, Inc. - Common Stock?
    The ticker symbol for Kezar Life Sciences, Inc. - Common Stock is KZR on the Nasdaq Stock Market
    What is the current price of Kezar Life Sciences, Inc. - Common Stock?
    The current price of Kezar Life Sciences, Inc. - Common Stock is 6.250
    When was Kezar Life Sciences, Inc. - Common Stock last traded?
    The last trade of Kezar Life Sciences, Inc. - Common Stock was at 01/06/26 04:00 PM ET
    What is the market capitalization of Kezar Life Sciences, Inc. - Common Stock?
    The market capitalization of Kezar Life Sciences, Inc. - Common Stock is 452.55M
    How many shares of Kezar Life Sciences, Inc. - Common Stock are outstanding?
    Kezar Life Sciences, Inc. - Common Stock has 453M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.